Inactive Instrument
Progenics Pharmaceuticals, Inc. Stock
Stocks
US7431871067
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/19/20 | Issuer sale | Director | 56,393 | 0.0651% | ||
| 6/19/20 | Issuer sale | Director | 170,000 | 0.1963% | ||
| 6/19/20 | Issuer sale | Executive/Senior Manager | 389,864 | 0.4502% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +1.49% | - | - | 355M | |
| +10.00% | +5.18% | +54.35% | +71.20% | 60.57B | |
| +1.70% | +5.18% | +22.67% | +99.88% | 55.51B | |
| +3.02% | +2.13% | +10.84% | +76.18% | 55.22B | |
| +0.51% | -5.48% | +25.02% | +32.93% | 43.27B | |
| +5.19% | +0.45% | +21.29% | +91.21% | 40.36B | |
| +0.60% | +3.34% | +232.96% | +805.36% | 41.63B | |
| -3.79% | -7.50% | +89.46% | +78.72% | 33.29B | |
| +5.32% | +6.04% | +20.27% | +52.98% | 32.27B | |
| +1.57% | +8.71% | -42.32% | +342.24% | 22.91B | |
| Average | +2.45% | +5.02% | +48.28% | +183.41% | 42.78B | |
| Weighted average by Cap. | +3.17% | +4.06% | +50.52% | +168.48% |
Employees
-
